A Phase 1B, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination With Toripalimab With or Without Other Treatments in Participants With Advanced or Metastatic Solid Tumors
Latest Information Update: 04 Dec 2024
Price :
$35 *
At a glance
- Drugs CHS 114 (Primary) ; Toripalimab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Head and neck cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Coherus Biosciences
- 03 Dec 2024 According to Coherus BioSciences Media Release, the company expects initiating 2L head and neck squamous cell carcinoma (HNSCC) and 2L gastric cancer in Q1 2025 with a first data readout expected in Q2 2026.
- 06 Nov 2024 According to Coherus BioSciences Media Release, initial data from this study is expected in the first half of 2026.
- 28 Oct 2024 New trial record